

Curriculum Vitae

Dena Firouzabadi

Pharm D., PhD in Clinical Pharmacy

Personal Information:

Date of birth: September 21st, 1985

Place of birth: Shiraz, Iran

Marital status: Married

Educational Qualifications:

1999-2003 High School: Daneshgah School, Shiraz

2003-2010 PharmD: Shiraz University of Medical Sciences, School of Pharmacy

2014-2019: Residency in Clinical Pharmacy, Shiraz University of Medical Sciences

Employment History:

Late 2010- late 2012: 2-year period of service commitment in return for 7 years of free education (PharmD Degree) at Namazi Hospital, Clinical Pharmacy Department and Amir Oncology Hospital.

2010-2013: Pharmacist of Dena Hospital Pharmacy (Afternoon Shift). Also taking part in annual hospital pharmacy courses as the presenter.

2020- 2022: Shahid Faghihi Hospital; Clinical Pharmacy Department.

2022-now: Assistant professor at Shiraz School of Pharmacy- Shiraz University of Medical Sciences

Administrative Positions:

2005: Scientific committee member of the 11th Annual Iranian Pharmacy Students Seminar (IPSS)

2016: Scientific committee member of the 1st Iranian Hematopathology Conference

2014-2020: Editor at the journal of “Trends in Pharmaceutical Sciences” (TIPS)

2020-2022: Reviewer at the journal of “Trends in Pharmaceutical Sciences” (TIPS)

Achievements

2001: Junior and Senior proficiency in English language (Iran Language Institute)

2003: University entrance exam (konkooor); Rank in Iran: 207

2003-2004: First rank among Shiraz pharmacy students of the year 1382.

2005-2006: Third rank among Shiraz pharmacy students of the year 1382.

2010: PharmD degree dissertation defense grade, 20/20

2003-2010: Overall second rank in between Shiraz pharmacy students of the entrance year 1382, with average graduate grade of 18.4 out of 20.

2009: Elected as student of the year and awarded by the Iranian president of the time.

2010: Awarded for contribution to achievement of ISO9001:2008 certificate of food and drug reference lab affiliated to Shiraz University of Medical Sciences.

2012: Awarded by the education deputy of Namazi hospital for performing valuable services associated to clinical pharmacy department.

2014: Clinical pharmacy entrance exam. Rank in Iran: 4th

2016: Second rank in first year residency promotion exam.

2017: First rank in second year residency promotion exam among same year residency program students.

2018: Second rank in Shiraz clinical pharmacy board examination.

2019: PhD degree dissertation defense grade: 20/20

2019: PhD degree graduate grade: 18.8/20

Conference Attendance:

2005: Research committee of Iranian Pharmacy Students' Seminar (IPSS)

2006: 10th Iranian Pharmaceutical Sciences Conference, Poster presentation

2009: 2nd Iranian Clinical Pharmacy Congress, Attendance

2012: 1st Iranian Cosmeceutical Congress, Presentation

2015: 6th Iranian Clinical Pharmacy Congress, Poster presentation

2015: 19th Iranian Pharmacy Students' Seminar (IPSS), Poster reviewer

2018: 9th Iranian Clinical Pharmacy Congress, Poster presentation

2018: 21st Iranian Pharmacy Students' Seminar (IPSS), Reviewer

2020: 42nd National Congress of Pharmacy in Iran, Panel Presentation

2021: 20th Congress of Iranian Society of Medical Oncology and Hematology, Panel Presentation

Workshops:

2009: Safety and protection in biomedical laboratories, Shiraz University of Medical Sciences

2016: Scientific writing, Shiraz University of Medical Sciences

2017: Professional ethics, Shiraz University of Medical Sciences

2019: Design and analysis of clinical trials, Shiraz University of Medical Sciences

2020: Prescription Drug Regulation, Cost, and Access: Current Controversies in Context, HarvardX, Online workshop held by Harvard University

2020: COVID-19 Training for Healthcare Workers, Stanford University Online Course

2020: Systematic Review, Shiraz University of Medical Sciences

2022: Key speaker (two 2h sessions) for the pharmacy students' summer school (hematologic malignancies and solid tumors)

Research Projects:

1. Association of predictive markers in tumor response to neoadjuvant chemotherapy in locally advanced breast cancer. (*Main Collaborator, 2017*)
2. The addition of carboplatin as second line neo-adjuvant chemotherapy in locally advanced breast cancer. (*PhD Candidate Contribution, 2017*)
3. Evaluation of advanced deep learning approach for ki67 stained hotspot detection and proliferation rate scoring for prognostic evaluation of breast cancer in Shiraz. (*PhD Candidate Contribution, 2019*)
4. Evaluation of the effect of androgen receptor expression on response rate to neoadjuvant chemotherapy in locally advanced breast cancer patients referred to oncology clinics affiliated to Shiraz University of Medical Sciences. (*Main Collaborator, 2020*)

5. Impact of mood disorder, anti-depressant medication use and inflammatory marker, CRP, on the outcome of COVID-19 patients. (*Main Collaborator, 2020*)
6. Impact of COVID-19 on health-related quality of life 5 months after the acute infection (*Main Collaborator, 2021*)
7. Impact of Tocilizumab use on developing infection in ICU-admitted COVID-19 patients (*Main Collaborator, 2022*)
8. Impact of Tocilizumab on normalizing inflammatory marker such as CRP, ESR, WBC and its sustained effect on CRP levels (*Main Collaborator, 2022*)

Publications:

1. Iranpoor N, Firouzabadi H, Nowrouzi N, **Firouzabadi D**. Highly chemoselective nitration of aromatic amines using the Ph₃P/Br₂/AgNO₃ system. Tetrahedron letters. 2006 Sep 18;47(38):6879-81.
2. Kheshti R, Namazi S, Mehrabi M, **Firouzabadi D**. Health care workers' knowledge, attitude, and practice about chronic pain management, Shiraz, Iran. Anesthesiology and Pain Medicine. 2016 Aug;6(4).
3. Vazin A, Karimzadeh I, Zand A, Hatami-Mazinani N, **Firouzabadi D**. Evaluating adherence of health-care team to standard guideline of colistin use at intensive care units of a referral hospital in Shiraz, Southwest of Iran. Advanced pharmaceutical bulletin. 2017 Sep;7(3):391.
4. Karamikhah R, **Firouzabadi D**, Bahmani S, Vazin A. Cost estimation related to drug waste in two major pediatric referral centers and one adult hospital in southern Iran: comparative cross-sectional study. Trends Pharma Sci. 2018;4(1).
5. **Firouzabadi D**, Firouzabadi N, Kalani K, Zomorrodian K, Tehrani ES. Response to sertraline is influenced by GN β 3 gene G-350A variant in patients with major depressive disorder. European journal of clinical pharmacology. 2019 Feb 6;75(2):189-94.

6. **Firouzabadi D**, Mahmoudi L. Knowledge, attitude, and practice of health care workers towards antibiotic resistance and antimicrobial stewardship programmes: A cross-sectional study. *Journal of evaluation in clinical practice*. 2019 May 21.
7. **Firouzabadi D**, Rezvani A, Dehghanian A, Mahmoudi L. Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran. *Cancer management and research*. 2019;11:6489.
8. Shafiekhani M, Moosavi N, **Firouzabadi D**, Namazi S. Impact of clinical pharmacist's interventions on potential drug–Drug interactions in the cardiac care units of two university hospitals in Shiraz, South of Iran. *Journal of research in pharmacy practice*. 2019 Jul;8(3):143.
9. Mahmoudi L, Sepasian A, **Firouzabadi D**, Akbari A. The Impact of an Antibiotic Stewardship Program on the Consumption of Specific Antimicrobials and Their Cost Burden: A Hospital-wide Intervention. *Risk Management and Healthcare Policy*. 2020;13:1701.
10. **Firouzabadi D**, Dehghanian A, Rezvani A, Mahmoudi L, Talei A. Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial. *BMC cancer*. 2021 Dec;21(1):1-13.
11. Negahbani F, Sabzi R, Jahromi BP, **Firouzabadi D**, Movahedi F, Shirazi MK, Majidi S, Dehghanian A. PathoNet introduced as a deep neural network backend for evaluation of Ki-67 and tumor-infiltrating lymphocytes in breast cancer. *Scientific reports*. 2021 Apr 19;11(1):1-3.
12. Firouzabadi N, Ghazanfari N, Alavi-Shoshtari A, **Firouzabadi D**, Haem E. Angiotensin-converting enzyme genetic variants do not influence response to risperidone in autistic children. *Trends in Pharmaceutical Sciences*. 2022 Sep 1;8(3):165-74.
13. **Firouzabadi D**. Evolution of SARS-CoV-2; The Omicron Variant and its Considerations, A Mini Review. *Trends in Pharmaceutical Sciences*. 2022 Jun 1;8(2):119-26.
14. Salehi M, Khalili H, Seifi A, Davoudi H, Darazam IA, Jahangard-Rafsanjani Z, Mohammadnejad E, Heydari B, Siahkaly SJ, Tabarsi P, Kalantari S, ..., **Firouzabadi D**.

Antibiotic use during the first 6 months of COVID-19 pandemic in Iran: A large-scale multi-centre study. *Journal of Clinical Pharmacy and Therapeutics*. 2022 Aug 21.

15. **Firouzabadi D**, Kheshti F, Abdollahifard S, Taherifard E, Kheshti MR. The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis. *Health science reports*. 2022 Nov;5(6):e892.

16. Alimoradi N, Sharqi M, **Firouzabadi D**, Sadeghi MM, Moezzi MI, Firouzabadi N. SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease. *Virology Journal*. 2022 Dec;19(1):1-9.